SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma

Blood

Volumn 118, Issue 1, 2011, Pages 37-43

  Casasnovas, René Olivier ^a   Meignan, Michel ^b   Berriolo Riedinger, Alina ^c   Bardet, Stéphane ^d   Julian, Anne ^e   Thieblemont, Catherine ^f   Vera, Pierre ^g   Bologna, Serge ^h   Brière, Josette ^f   Jais, Jean Philippe ⁱ   Haioun, Corinne ^b   Coiffier, Bertrand ^j   Morschhauser, Franck ^k  

^a HÔPITAL DU BOCAGE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CHU PURPAN   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CENTRE HENRI BECQUEREL   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j CENTRE HOSPITALIER LYON SUD   (France)

^k UNIV LILLE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ADULT; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; IMAGE ANALYSIS; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MAXIMAL STANDARDIZED UPTAKE VALUE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL;

EID: 79960116662     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-327767     Document Type: Article

References (18)

1. Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25(7):721-728. (Pubitemid 28377035)
2. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19(2):414-419. (Pubitemid 32112853)
3. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-518.
4. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
5. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906-1914.
6. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4):1376-1381. (Pubitemid 41129604)
7. Dupuis J, Itti E, Rahmouni A, Hemery F, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20(3):503-507.
8. Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced- stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010(11);28:1896-1903.
9. Horning SJ, Juweid ME, Schöder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115(4):775-777.
10. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48(10): 1626-1632. (Pubitemid 47572710)
11. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009; 50(4):527-533.
12. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27(16):2739-2741.
13. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PETScan in Lymphoma. Leuk Lymphoma. 2009; 50(12):1257-1260.
14. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37-46.
15. Zweig MH, Campbell G. Receiver-operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4): 561-577. (Pubitemid 23118304)
16. Casasnovas RO, Saverot AL, Berriolo Riedinger A, et al. The 18F-FDG SUVmax reduction after two cycles of R-CHOP regimen predicts progression free survival of patients with diffuse large B-cell lymphoma [abstract]. Blood. 2009;114(22):Abstract 2931.
17. Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010;51(12): 1857-1862.
18. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.